| 2005-11-16: |
Takeda's ACTOS( R ) ( pioglitazone ) Reduces Risk of Further Heart Attack by 28 Percent in Patients With Type - 2 Diabetes
London, November 16 ( PRN/ots ) - - For Non - US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ACTOS( R ) ( pioglitazone ) significantly reduced the occurrence (...) |
| 2010-03-23: |
Hyglos GmbH - New Reliable and Sensitive Method for Direct Endotoxin Detection
Munich, Germany ( na Originaltextservice ) - Hyglos GmbH introduces a ground - breaking solution for pharmaceutical and biotechnological endotoxin - testing based on its proprietary phage - ligand technology. Bacterial endotoxin technology that uses bacteriophage - derived components has the potential to efficiently detect lipopolysaccharides ( LPS ) contaminations (...) |
| 2007-12-04: |
International Day of Disabled Persons
Toronto ( PRN/ots ) - "Governments need to recognize the rights and needs of people with disabilities," says Prof. Allen Foster, President of CBM on the International Day of Disabled Persons. Millennium Development Goals set out by the United Nations will not be achieved (...) |
| 2007-05-03: |
Isotechnika Selected for Oral Presentation at the American Transplant Congress
Edmonton, Canada ( PRN/ots ) - - Trades on Toronto Stock Exchange - ( TSX:ISA ) Isotechnika today announced that the Company has been selected to give an oral presentation during the American Transplant Congress in San Francisco, California. An overview of the latest Phase 2b (...) |
| 2009-06-25: |
ONGLYZA( TM ) ( saxagliptin ) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( NYSE: BMY ) and AstraZeneca ( LSE: AZN ) today announced that their marketing authorisation application for ONGLYZA( TM ) ( saxagliptin ) received a positive opinion from the Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of type (...) |
| 2007-06-21: |
Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, a bio - pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, (...) |
| 2005-11-22: |
Degussa endows European research award / EU Commissioner Janez Potocnik as patron
Dusseldorf ( na Originaltextservice ) - Embargoed until November 22, 6.30 pm The new European "Science - to - Business Award” of Degussa AG, Dusseldorf, Germany, is more than just a totally new kind of award for innovation at the pan - European level with prize money (...) |
| 2007-05-14: |
Wyeth and Progenics Pharmaceuticals Announce Submission of Marketing Application in Europe for the Subcutaneous Formulation of Methylnaltrexone
Collegeville, Pennsylvania and Tarrytown, New York ( PRN/ots ) - - Application for the Treatment of Opioid - Induced Constipation in Patients with Advanced Illness - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), and Progenics Pharmaceuticals, Inc. ( Nasdaq: PGNX ) announced today that Wyeth has submitted a (...) |
| 2011-01-31: |
Hoya Announces Third Quarter Financial Results
Tokyo ( PRN/ots ) - HOYA Corporation today announced financial results for the third quarter ended December 31, 2010. Net sales were up 1.5 Prozent to 108,449 million yen year - on - year, and operating income rose 4.7 Prozent to 19,897 million yen. Net income was up 12.0 Prozent to (...) |
| 2007-05-18: |
FDA Approves Lovenox( R ) ( Enoxaparin Sodium Injection ) for the Most Severe Type of Heart Attack
Paris ( PRN/ots ) - - Lovenox( R ) is the Low - Molecular Weight Heparin, Approved in the United States for the Broadest Range of Indications Sanofi - aventis announced today that the Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the (...) |
| 2008-12-09: |
VELCADE( R ) ( bortezomib ) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations
Beerse, Belgium ( PRN/ots ) - - Preliminary Phase II Re - treatment Results and two new Analyses From Phase III VISTA Presented at ASH Annual Meeting Janssen - Cilag today announced preliminary results from a prospective, international, multicenter, open - label, phase II study showing re - treatment (...) |
| 2010-10-22: |
New JUPITER Analysis Demonstrates CRESTORTM ( rosuvastatin ) Significantly Reduces Major Cardiovascular Events in High Risk Patients
London ( PRN/ots ) - A post - hoc - analysis from JUPITER published in the European Heart Journal shows CRESTOR( TM ) ( rosuvastatin ) 20 mg significantly reduced major cardiovascular ( CV ) events, defined as the combined end - point of CV death, stroke and myocardial infarction, compared to placebo, by 50 Prozent (...) |
| 2009-09-22: |
Vectibix( R ) in Combination With Chemotherapy Significantly Improves Progression - Free Survival in Second - Line Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix( R ) ( panitumumab ) in combination with FOLFIRI ( an irinotecan based chemotherapy ), as a second - line treatment for metastatic colorectal cancer ( mCRC ). In this trial, Vectibix (...) |
| 2008-10-31: |
Largest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem
Ingelheim, Germany ( PRN/ots ) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under - Recognised and Under - Diagnosed - For non - US media only Results from the PRESIDE*( 1 ) survey, (...) |
| 2009-02-12: |
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq( R ) ( dronedarone ) in Atrial Fibrillation
Paris ( PRN/ots ) - - Multaq( R ) ( dronedarone ) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation Sanofi - aventis ( Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY ) announced today that the ATHENA trial was published (...) |
| 2006-09-19: |
Young Physicians Call for Better Medical School Training in Depression
Paris ( PRN/ots ) - - Multi - National Survey Highlights Gaps in PCPs Knowledge About Depression and Painful Physical Symptoms Nine of 10 young primary care physicians ( PCPs ) believe medical school training about depression - - specifically regarding its painful physical symptoms - - needs to be improved, according (...) |
| 2008-11-20: |
Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Cork, Ireland, November 20 ( PRN/ots ) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir ( VX - 950 ), an investigational protease inhibitor ( PI ), in patients with chronic genotype 1 hepatitis (...) |
| 2005-01-27: |
Breakthrough Drug Tarceva Provides New Hope for Patients With Advanced Pancreatic Cancer
Basel, Switzerland ( PRN/ots ) - - New data shows significant improvement in overall survival when Tarceva is added to chemotherapy New data, presented for the first time today, have shown that adding Tarceva ( erlotinib ) to chemotherapy improves survival in patients with locally advanced or (...) |
| 2008-09-03: |
Resverlogix Board of Directors Update
Calgary, Canada ( PRN/ots ) - - Provides Shareholders With an Update on Strategic Review Activities On behalf of Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) the Board of Directors, due to the recent advancement of various discussions with third parties, feel it is (...) |
| 2007-08-02: |
FDA Allows Long Term Use of ISA247 in Isotechnika Phase 2b Kidney Transplant Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika today announced that the Company has received permission from the Food and Drug Administration of the United States ( FDA ) for the long term use of ISA247 in patients currently participating in the Company's Phase 2b kidney transplant ( PROMISE ) trial. (...) |
| 2010-09-20: |
24 - Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin ( HbA1c ) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
Stockholm ( PRN/ots ) - Bristol - Myers Squibb Company ( http://www.bms.com ) and AstraZeneca ( http://www.astrazeneca - us.com ) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride ( sulphonylurea ) therapy produced significant reductions in glycosylated (...) |
| 2006-06-27: |
INSTI( TM ) a 60 Second HIV Testing Kit is Now Available to the European Community
Richmond, Canada ( PRN/ots ) - bioLytical( TM ) Laboratories announced today, that their INSTI( TM ) kit, a rapid HIV antibody test developed by the company, received CE Mark approval in their European Community. "We are delighted to have received CE Mark approval for INSTI," says Robert Mackie, President (...) |
| 2007-07-12: |
SemBioSys Achieves Critical Apo AI Milestone
Calgary, Canada ( PRN/ots ) - - Canadian Biotechnology Company is the First Company in the World to Produce Recombinant Apo AI, a Next Generation Cardiovascular Therapy, Using Plants SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company, today announced it has successfully developed commercial levels (...) |
| 2010-01-14: |
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Abbott Park, Illinois ( PRN/ots ) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment (...) |
| 2006-01-12: |
Early detection of cervical cancer: Wolfsburg breaks new ground
Dreieich/Wolfsburg ( na Originaltextservice ) - The city of Wolfsburg is home to Volkswagen, the car makers. Its reputation to date has mainly been as a motor of progress in the development of modern production methods for the automotive industry. But Wolfsburg is now about to make (...) |
| 2008-06-10: |
New Data Shows Pramipexole ( Mirapexin( R )/Sifrol( R ) ) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome ( RLS )
Ingelheim, Germany ( PRN/ots ) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS - Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole ( Mirapexin( R )/Sifrol( R ) ) can significantly reduce RLS - associated limb pain in patients with (...) |
| 2011-04-11: |
Veterinarians and Pet Owners Urged to act Upon Evolving Dangers Posed by CVBDs
Monheim, Germany ( PRN/ots ) - Leading experts from around the world came together today to share their latest research findings at the 6th Canine Vector Borne Disease ( CVBD ) forum in Nice, France and call for greater awareness of the dangers posed to animals and humans (...) |
| 2011-04-22: |
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA( R ) ( Edoxaban ), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism After Major Orthopedic Surgery
Tokyo ( PRN/ots ) - Daiichi Sankyo Company, Limited ( hereafter, Daiichi Sankyo ), announced today that the company has received its first marketing approval for LIXIANA( R ) ( JAN: Edoxaban Tosilate Hydrate, INN:edoxaban ) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in (...) |
| 2007-06-07: |
Innovative New Anaemia Drug MIRCERA Demonstrates Ability to Maintain Tight Haemoglobin Levels at Once Monthly Dosing in Dialysis Patients With Chronic Kidney Disease
Basel, Switzerland ( PRN/ots ) - - First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi - centre renal anaemia study show that switching patients directly from frequent doses of epoetin therapies ( epoetin alfa or (...) |
| 2006-03-17: |
Significant Long Term Efficacy of Protelos( R ) ( Strontium Ranelate ) Confirmed
Vienna, Austria ( PRN/ots ) - - New Data Demonstrate "Unique", Five Year Anti - Osteoporotic Efficacy Against Both Vertebral and Non - Vertebral Fractures New five year data presented at the 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis ( ECCEO 6 ) meeting (...) |
| 2006-07-13: |
Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces
Toronto ( PRN/ots ) - Medify Solutions Limited today announces its own in - house product for roll out to the NHS. This new capability will replace the legacy generic solution provided for Medify by Pervasic and specifically focuses on the known requirements of Healthcare professionals (...) |
| 2008-11-21: |
New Antibiotic Against Serious Infections
Beerse, Belgium, November 21 ( PRN/ots ) - - European Authority Recommends Approval of ZEVTERA( TM ) BEERSE, Belgium, November 21 /PRNewswire/ - - - A Broad - spectrum, Anti - MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections BEERSE, Belgium, November 21 /PRNewswire/ - - The Committee for (...) |
| 2009-10-30: |
Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival
London ( PRN/ots ) - - Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. ( Headquarters: Tokyo, President and CEO: Haruo Naito ) today announced preliminary results from a recently completed Phase III study with (...) |
| 2005-06-16: |
Syrian - Lebanese Hospital Concludes Largest Private Scientific - Social Agreement in Brazil
Sao Paulo, Brazil ( PRN/ots ) - - Miguel Nicolelis - - World - renowned Brazilian Neuroscientist - - to Perform the First Operation on a Human That Will Allow the Brain to Control Robotic Arms The Teaching and Research Institute of the Syrian - Lebanese Hospital in Sao Paulo (...) |
| 2004-10-08: |
Degussa fosters Professorship in Organic Synthetic Methods / Prof. Magnus Rüping follows call to Frankfurt on Main University
Dusseldorf ( na Originaltextservice ) - - Cross - reference: photo was sent via satellite and is available at http://www.presseportal.de/galerie.html Yesterday, Prof. Magnus Rüping ( 32 ) held his inaugural lecture in connection with the Professorship in Organic Synthetic Methods endowed on Johann Wolfgang Goethe (...) |
| 2008-06-13: |
New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact
Paris ( PRN/ots ) - - Lack of Physician Education May Contribute to Problem A new global survey of fibromyalgia patients and physicians shows that fibromyalgia, a chronic widespread pain condition, results in poor quality of life and poses a financial burden on patients (...) |
| 2007-06-14: |
Boehringer Ingelheim Initiates SPRING Study of Aptivus( R ) ( tipranavir ) in Diverse Group of Highly Treatment - Experienced HIV - Positive Patients
Ingelheim, Germany ( PRN/ots ) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment - experienced HIV - 1 infected (...) |
| 2004-09-07: |
LAF237, First in a New Class of Oral Antidiabetic Agents, Shown in Phase II to Provide Clinically Significant Improvement in Glycemic Control
Munich, Germany ( PRN/ots ) - - Researchers conclude LAF237 positively influences both insulin production and utilisation in type 2 diabetes The investigational drug LAF237, the first in a new class of oral anti - diabetes agents, significantly improved glycemic control in patients with type 2 (...) |
| 2010-12-08: |
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Hip Replacement
Tokyo ( PRN/ots ) - Daiichi Sankyo Company, Limited announced that its investigational once - daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin sodium in preventing venous thromboembolic ( VTE ) events in patients following total hip replacement ( THR ), a type of major (...) |
| 2009-05-07: |
AMT Starts Preregistration Trial for Glybera( TM )
Amsterdam ( PRN/ots ) - Amsterdam Molecular Therapeutics ( Euronext: AMT ), a leader in the field of human gene therapy, announced today the treatment of the first patient in a preregistration clinical trial with Glybera( TM ). This gene therapy product targets lipoprotein lipase deficiency ( LPLD ), a seriously debilitating and (...) |
| 2010-03-10: |
Chronic Kidney Disease and Diabetes - Major Risk Factors Amongst Europe's Population to Be Urgently Addressed
Strasbourg, France, March 10, 2010 ( PRN/ots ) - The European Kidney Health Alliance ( EKHA ) and World Kidney Day ( WKD ) organisations today call for European Union ( EU ) support. Early awareness, identification and treatment of chronic kidney disease ( CKD ) and its associated diseases, including diabetes - the leading cause (...) |
| 2010-09-01: |
DAIICHI SANKYO Announces Enrollment in the Two Largest Single Phase III Trials so far for the Prevention of Stroke in AF and for the Treatment of VTE is Proceeding as Planned
Stockholm ( PRN/ots ) - DAIICHI SANKYO announced today that the ongoing trials ENGAGE AF - TIMI 48 ( The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation ) and HOKUSAI VTE with their investigational factor Xa inhibitor edoxaban are enrolling in accordance to plan. The projected recruitment (...) |
| 2008-06-16: |
Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
Lyon, France and Swiftwater, Pennsylvania ( PRN/ots ) - Sanofi Pasteur, the vaccines division of sanofi - aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization ( WHO ) over 3 years for the establishment of an H5N1 (...) |
| 2011-03-10: |
Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing
Irvine, California and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced the hiring of David Macdonald as the company's Chief Operating Officer, Mark Willig as Executive Vice President of North American Sales, and Doug Bradley as Vice President (...) |
| 2007-02-23: |
Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product
New York ( PRN/ots ) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S - - the largest pharmaceutical wholesaler in Denmark - - that prohibits the sale of a generic version of Lipitor by generics manufacturer Ranbaxy. The injunction, (...) |
| 2009-03-19: |
Occlutech obtains favourable ruling in proceedings initiated by AGA Medical
Jena ( na Originaltextservice ) - Occlutech GmbH today announced that it had defeated a request for insolvency, launched at the Amtsgericht Gera in Germany by its US competitor AGA Medical. The request by AGA was based on wrongful assumptions about Occlutech, and AGA announced (...) |
| 2007-10-15: |
Valdoxan( R ), the First Melatonergic Antidepressant, Confirms its Efficacy in Preventing Relapse Whatever the Severity of the Depression
Vienna, Austria ( PRN/ots ) - Valdoxan( R ) ( agomelatine ), the first melatonergic antidepressant, is an effective, long - term treatment for Major Depressive Disorder ( MDD ) according to new data presented today at the European College of Neurospsychopharmacology ( ECNP ) annual congress. The new international study showed Valdoxan's efficacy in preventing (...) |
| 2005-04-13: |
Theriak Software Adopted at Central Pharmacy in Germany
Reykjavik, Iceland ( PRN/ots ) - Theriak Medication Management, a software system from TM Software for use in healthcare operations, went into commission yesterday at a central hospital pharmacy in Bottrop, a city in the Rühr district in Germany. The pharmacy serves hospitals in the nearby (...) |
| 2005-12-08: |
Isotechnika Announces Nine Month Safety Data From the Phase III Psoriasis Trial for ISA247
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX:ISA ) announced today nine month interim safety and efficacy data obtained from its 24 week Phase III psoriasis trial and 12 week extension for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
